Reduced hippocampal glutamate in Alzheimer disease

Neurobiology of Aging

Volumn 32, Issue 5, 2011, Pages 802-810

  Rupsingh, R ^a,b   Borrie, M ^b,c   Smith, M ^c   Wells, J L ^b,c   Bartha, R ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer disease; Glutamate; Hippocampus; MCI (mild cognitive impairment); MRS; Spectroscopy

Indexed keywords

CREATINE; GLUTAMIC ACID; INOSITOL; N ACETYLASPARTIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA RATING SCALE II; HIPPOCAMPUS; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; RIGHT HEMISPHERE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHOLINE; CREATINE; FEMALE; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE;

EID: 79954569500     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.05.002     Document Type: Article

References (51)

1. Ackl N., Ising M., Schreiber Y.A., Atiya M., Sonntag A., Auer D.P. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 2005, 384(1-2):23-28.
2. Adalsteinsson E., Sullivan E.V., Kleinhans N., Spielman D.M., Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000, 355(9216):1696-1697.
3. Alexopoulos G.S., Abrams R.C., Young R.C., Shamoian C.A. Cornell scale for depression in dementia. Biol. Psychiatry 1988, 23(3):271-284.
4. Antuono P.G., Jones J.L., Wang Y., Li S.J. Decreased glutamate+glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5T. Neurology 2001, 56(6):737-742.
5. Ashburner J., Friston K. Multimodal image coregistration and partitioning-a unified framework. Neuroimage 1997, 6(3):209-217.
6. Barnes J., Scahill R.I., Schott J.M., Frost C., Rossor M.N., Fox N.C. Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. Dement. Geriatr. Cogn. Disord. 2005, 19(5-6):338-344.
7. Bartha R., Drost D.J., Menon R.S., Williamson P.C. Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0Tesla. Magn. Reson. Med. 2000, 44(2):185-192.
8. Bartha R., Drost D.J., Menon R.S., Williamson P.C. Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction. Magn. Reson. Med. 2000, 44(4):641-645.
9. Bartha R., Drost D.J., Williamson P.C. Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed. 1999, 12(4):205-216.
10. Bartha R., Smith M., Rupsingh R., Rylett J., Wells J.L., Borrie M.J. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(3):786-793.
11. Bell K.F., Bennett D.A., Cuello A.C. Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment. J. Neurosci. 2007, 27(40):10810-10817.
12. Braak H., Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol. Aging 1994, 15(3):355-356. (discussion 379-380).
13. Brand A., Richter-Landsberg C., Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 1993, 15(3-5):289-298.
14. Christiansen P., Henriksen O., Stubgaard M., Gideon P., Larsson H.B. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn. Reson. Imaging 1993, 11(1):107-118.
15. de Graaf A.A., van Dijk J.E., Bovee W.M. QUALITY: quantification improvement by converting lineshapes to the Lorentzian type. Magn. Reson. Med. 1990, 13(3):343-357.
16. Dixon R.M., Bradley K.M., Budge M.M., Styles P., Smith A.D. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 2002, 125(Pt 10):2332-2341.
17. Ernst T., Chang L., Melchor R., Mehringer C.M. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997, 203(3):829-836.
18. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12(3):189-198.
19. Frahm J., Haase A., Matthaei D. Rapid three-dimensional MR imaging using the FLASH technique. J. Comput. Assist. Tomogr. 1986, 10(2):363-368.
20. Frederick B.D., Lyoo I.K., Satlin A., Ahn K.H., Kim M.J., Yurgelun-Todd D.A., Cohen B.M., Renshaw P.F. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(8):1313-1322.
21. Garwood M., DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 2001, 153(2):155-177.
22. Haley A.P., Knight-Scott J., Fuchs K.L., Simnad V.I., Manning C.A. Shortening of hippocampal spin-spin relaxation time in probable Alzheimer's disease: a 1H magnetic resonance spectroscopy study. Neurosci. Lett. 2004, 362(3):167-170.
23. Hattori N., Abe K., Sakoda S., Sawada T. Proton MR spectroscopic study at 3Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002, 13(1):183-186.
24. Hyman B.T., Van Hoesen G.W., Damasio A.R. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann. Neurol. 1987, 22(1):37-40.
25. Isobe T., Matsumura A., Anno I., Yoshizawa T., Nagatomo Y., Itai Y., Nose T. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn. Reson. Imaging 2002, 20(4):343-349.
26. Jessen F., Block W., Traber F., Keller E., Flacke S., Lamerichs R., Schild H.H., Heun R. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001, 57(5):930-932.
27. Kaiser L.G., Schuff N., Cashdollar N., Weiner M.W. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4T. Neurobiol. Aging 2005, 26(5):665-672.
28. Kantarci K., Jack C.R., Xu Y.C., Campeau N.G., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Kokmen E., Tangalos E.G., Petersen R.C. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000, 55(2):210-217.
29. Kantarci K., Reynolds G., Petersen R.C., Boeve B.F., Knopman D.S., Edland S.D., Smith G.E., Ivnik R.J., Tangalos E.G., Jack S C.R. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3T. AJNR Am. J. Neuroradiol. 2003, 24(5):843-849.
30. Kantarci K., Weigand S.D., Petersen R.C., Boeve B.F., Knopman D.S., Gunter J., Reyes D., Shiung M., O'Brien P.C., Smith G.E., Ivnik R.J., Tangalos E.G., Jack S C.R. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2007, 28(9):1330-1339.
31. Kassem M.N., Bartha R. Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4Tesla incorporating macromolecule subtraction. Magn. Reson. Med. 2003, 49(5):918-927.
32. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn. Reson. Med. 1990, 14:26-30.
33. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9(3):179-186.
34. Lin A.P., Shic F., Enriquez C., Ross B.D. Reduced glutamate neurotransmission in patients with Alzheimer's disease-an in vivo (13)C magnetic resonance spectroscopy study. Magma 2003, 16(1):29-42.
35. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(33):11906-11910.
36. Marquardt D.W. An algorithm for least-squares estimations of nonlinear parameters. J. Soc. Ind. Appl. Math. 1963, 11:431-441.
37. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., Ross B.D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993, 187(2):433-437.
38. Moats R.A., Ernst T., Shonk T.K., Ross B.D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 1994, 32(1):110-115.
39. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 1997, 9(Suppl. 1):173-176. (discussion 177).
40. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 2001, 58(12):1985-1992.
41. Rose S.E., Janke A.L., Chalk J.B. Gray and white matter changes in Alzheimer's disease: a diffusion tensor imaging study. J. Magn. Reson. Imaging 2008, 27(1):20-26.
42. Sasaki H., Muramoto O., Kanazawa I., Arai H., Kosaka K., Iizuka R. Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann. Neurol. 1986, 19(3):263-269.
43. Schuff N., Amend D., Ezekiel F., Steinman S.K., Tanabe J., Norman D., Jagust W., Kramer J.H., Mastrianni J.A., Fein G., Weiner M.W. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997, 49(6):1513-1521.
44. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27(11):2866-2875.
45. Sheikh J.I., Yesavage J.A., Brooks J.O., Friedman L, Gratzinger P., Hill R.D., Zadeik A., Crook T. Proposed factor structure of the geriatric depression scale. Int. Psychogeriatr. 1991, 3(1):23-28.
46. Smith G.E., Ivnik R.J., Malec J.F., Kokmen E., Tangalos E., Petersen R.C. Psychometric properties of the mattis dementia rating scale. Assessment 1994, 1(2):123-132.
47. Solfrizzi V., Panza F., Colacicco A.M., D'Introno A., Capurso C., Torres F., Grigoletto F., Maggi S., Del Parigi A., Reiman E.M., Caselli R.J., Scafato E., Farchi G., Capurso A. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004, 63(10):1882-1891.
48. Tkac I., Andersen P., Adriany G., Merkle H., Ugurbil K., Gruetter R. In vivo 1H NMR spectroscopy of the human brain at 7T. Magn. Reson. Med. 2001, 46(3):451-456.
49. Valenzuela M.J., Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001, 56(5):592-598.
50. van den Boogaart A., Ala-Korpela M., Jokisaari J., Griffiths J.R. Time and frequency domain analysis of NMR data compared: an application to 1D 1H spectra of lipoproteins. Magn. Reson. Med. 1994, 31(4):347-358.
51. Zahr N.M., Mayer D., Pfefferbaum A., Sullivan E.V. Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy. Cereb. Cortex 2008, 18(10):2241-2250.